|
|
Amrix - Newsfeeds
-
-
The company's proprietary products in the United States include: TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), FENTORA(R) (fentanyl buccal tablet) [C-II], PROVIGIL(R) (modafinil ...
-
-
Cephalon, Inc. (Nasdaq: CEPH) announced the journal Cancer has published a pivotal study demonstrating that TREANDA ® (bendamustine HCl) for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma (NHL) whose disease ...
-
-
The companys proprietary products in the United States include: NUVIGIL(R) (armodafinil) Tablets [C-IV], TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), FENTORA(R) (fentanyl buccal ...
-
-
The company's proprietary products in the United States include: NUVIGIL(R) (armodafinil) Tablets [C-IV], TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), FENTORA(R) (fentanyl buccal ...
-
-
Pretrial hearing Dec. 9. LIGHT, Angie A., 19, 31 Saddleback Road, Mashpee; larceny of more than $250 from person over age 60 and disabled, possession of cyclobenzaprine hydrochloride, Nov. 30 in Mashpee. Ordered to remain drug-free and submit to random screens.
-
-
In the past 50 years, or so, we have been told, "Stop smoking. It can kill you." Now, all of a sudden, people come out of the woodwork claiming pot smoking is harmless. Wow. Do they not know that research has shown marijuana smoking destroys brain cells ...
-
-
(Acorda Therapeutics) 4mg Rx scored tabs Initially: usually 4mg, may increase by 2–4mg as needed every 6–8 hrs to a max of 3 doses in 24hrs; max 12mg/dose and 36mg/day. Renal impairment (CrCl <25mL/min): reduce dose. May sprinkle contents of capsules ...
-
-
Cyclobenzaprine is used to help relax certain muscles in your body. It helps relieve the pain, stiffness, and discomfort caused by strains, sprains, or injuries to your muscles. However, this medicine does not take the place of rest, exercise or physical ...
-
-
The companys pain therapeutics portfolio comprises AMRIX for the relief of muscle spasm associated with acute painful musculoskeletal conditions; and FENTORA, EFFENTORA, ACTIQ, and generic OTFC products, which focus on treating breakthrough cancer pain in ...
-
-
PITTSBURGH, Dec. 1 /PRNewswire-FirstCall/ -- Mylan Inc. today confirmed that the company and its subsidiary, Mylan Pharmaceuticals Inc., have been sued by Cephalon Inc., Eurand Inc. and Anesta AG in connection with the filing of an Abbreviated New Drug ...
-
-
The company's products include central nervous disorder drugs, the muscle relaxant Amrix and the cancer drug Treanda. A statement from Cephalon on the guidance did not breakdown where the sales growth is coming from. The company reports earnings for the ...
-
-
Cephalon Inc. said it entered an agreement to settle a patent lawsuit over its muscle relaxant Amrix with Eurand and Impax Laboratories.Inc. Under the deal, Cephalon's Anesta unit and patent holder Eurand will grant Impax a non-exclusive, royalty-bearing ...
-
-
MONTVALE, N.J., Nov. 26 /PRNewswire/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patent listed by Anesta in connection with its Amrix(R) (cyclobenzaprine ...
-
-
... today confirmed that the company and its subsidiary, Mylan Pharmaceuticals Inc., have been sued by Cephalon Inc., Eurand Inc. and Anesta AG in connection with the filing of an Abbreviated New Drug Application (ANDA) for Cyclobenzaprine Hydrochloride ...
-
-
Sales of Amrix, the once-daily skeletal muscle relaxant by Cephalon, were $73.6 million in its first full year on the market. Cephalon continues to provide strong support for Amrix and recently realigned an expanded it’s sales force by nearly 50%.
-
-
The increase was due primarily to sales of PANCRELIPASE, to higher royalties, in particular from AMRIX by Cephalon, and to higher development fees. Product sales grew 19% or 9% at constant currency rates to EUR 24.1 million ($33.8 million) in the ...
-
-
Nuvigil, Treanda and Amrix will drive the company's growth this year, Baldino told investors and Wall Street analysts in a conference call Tuesday. The company also updated its guidance for 2009. It remains $2.175 to $2.225 billion. For the third ...
Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.
|
|
